Taisho sees Mexican OTC acquisitions as N American springboard
This article was originally published in Scrip
Helped by the strong yen, the year to date has seen a record value of overseas acquisitions by Japanese firms across all sectors, and Taisho Pharmaceutical is doing its bit to raise the total even further.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.